Coronavirus Breakthrough: New Study Highlights Senhwa Biosciences Silmitasertib as Potential Treatment for COVID-19
TAIPEI and SAN DIEGO, July 1, 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on Next Generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that its drug Silmitasertib was again identified as o...
Senhwa Biosciences Silmitasertib Named as Potential COVID-19 Therapy
SAN DIEGO, March 31, 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492) announced today that its drug Silmitasertib (CX-4945) was determined to be a potential treatment forCOVID-19. To date, COVID-19, has infected over 700,000 people and killed over 34,000 people worldwide. COVID-19 is a ...
Senhwa Biosciences Reports Positive Phase 1 Data of CX-5461 in Patients With Advanced Solid Tumors at 2019 SABCS
TAIPEI and SAN DIEGO, Dec. 12, 2019 /PRNewswire/ -- Senhwa Biosciences Inc. (TPEx: 6492), a clinical stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced positive results from its Phase 1 trial of CX-5461. C...
Senhwa Biosciences Silmitasertib / Basal Cell Carcinoma Trial Completed 1st Patient Enrollment
TAIPEI, and SAN DIEGO, April 17, 2019 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492) announced today that the clinical trial of Silmitasertib (CX-4945) for the treatment of Basal Cell Carcinoma (BCC) has enrolled its first patient at Texas Oncology,Texas, USA. The trial will be carried o...
